Biological Products, (No Diagnostic Substances) · ALAMEDA, CA, United States
$19.48
-8.16% (-$1.73)2026-07-31
Smart-Money SignalAccumulation · 61/100— Insiders are net buyers over 90 days ($56.3M, 18 buys vs 4 sales)
Price Performance
Historical data including institutional events
Company Profile
B
Benjamin Oakes
CEO & Executive Director
Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
- Founded
- 2017
- Employees
- 89
- Headquarters
- ALAMEDA, CA, United States
- Website
- www.scribetx.com
Peer ComparisonRevenue ($B)
▾Loading company sections...